Skip to main content
TipRanks
Go Ultimate75% OFF

C-Rad AB Class B (24C) AI Stock Analysis

3 Followers
DE:24C

C-Rad AB Class B

(Frankfurt:24C)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Very Low LeverageVery low leverage gives C-Rad substantial financial flexibility and limits refinancing pressure if operating conditions weaken. A conservative capital structure also leaves more capacity to fund product development, commercial expansion, or customer support without depending heavily on additional borrowing.
Negative Factors
Contracting RevenueContracting revenue indicates that current demand and deployment activity are not yet expanding consistently. If the decline persists, it can reduce operating leverage, limit investment capacity, and make it harder for C-Rad to convert its SGRT market opportunity into sustained earnings growth.

C-Rad AB Class B (24C) vs. iShares MSCI Germany ETF (EWG)

-50%-40%-30%-20%-10%0%10%20%DE:24C-27.46%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 74.29M
Dividend Yield
0.39%
Average Volume (3M)
41
Price to Earnings (P/E)
17.4
Beta (1Y)
0.40
Revenue Growth
-6.15%
EPS Growth
111.46%
Country
Germany
Employees
98
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

C-Rad AB Class B Business Overview & Revenue Model

Company Description

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient po...

C-Rad AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:24C against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B78OutperformSEK 62.28B97.6130.26%0.72%13.94%5.70%
SE:ALIF.BSE:ALIF.B74OutperformSEK 21.65B33.7411.32%0.85%1.62%63.45%
SE:XVIVOSE:XVIVO64NeutralSEK 6.17B47.925.89%―17.83%330.94%
SE:RAY.BSE:RAY.B63NeutralSEK 5.98B28.9522.61%2.29%3.16%-5.78%
SE:PAXSE:PAX57NeutralSEK 1.55B-306.14-1.22%―34.05%-144.96%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%DE:24CSE:ALIF.BSE:PAXSE:RAY.BSE:XVIVOSE:SECT.BDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:24C and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:24CC-Rad AB Class B2.19-0.83-27.58%
SE:ALIF.BAddLife AB Class B177.501.330.76%
SE:PAXPaxman AB66.804.807.74%
SE:RAY.BRaySearch Laboratories AB Class B174.30-36.24-17.21%
SE:XVIVOXvivo Perfusion AB196.0031.0018.79%
SE:SECT.BSectra AB Class B319.2042.0115.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.